Where does Novimmune SA rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Novimmune SA ranks #8,453 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Novimmune SA hold?

Novimmune SA holds 38 US utility patents granted between 2016 and 2023, spanning 8 technology areas.

What is Novimmune SA's Innovation Score?

Novimmune SA has an Innovation Score of 32.3 out of 100 (41st percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Novimmune SA focus on?

Novimmune SA's top technology area is C07K (Peptides) with 38 patents, ranking #252 of 3,615 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Novimmune SA's patent grant rate increasing or decreasing?

Novimmune SA's recent grant velocity is -27% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Novimmune SA's patents?

Novimmune SA's patents average 11.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Novimmune SA patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Novimmune SA

USPTO PatentsView assignee record - 38 granted patents across 8 technology areas, recorded in grant years 2016–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Novimmune ranks #8,453 of 49,997 tracked US assignees by granted-patent volume, with 38 patents across 8 technology areas.

#8,453
of 49,997 US assignees by volume: 41st percentile
by Innovation Score (32.3/100): 11.4
avg claims per patent: -27%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R8453 · Foreign Corporation #8,453 · 38 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 38 grants
UPPER-Q #8,453/49,997
PHOTO-FINISH National Chain
CPC-NARROW C07K · 8 areas
INNOV-THIN 32.3/100
CLAIMS-PAR 11.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -27% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: National Chain Company (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Novimmune’s 32.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.7 pts (39%) Velocity 2.9 pts (9%) Breadth 10.0 pts (31%) Claim depth 6.8 pts (21%)

Qualcomm Incorporated · highest

85
Domo · near

32
Novimmune · this assignee

32
Portola Pharmaceutic… · near

32
SPD Swiss Precision… · near

32
Stat Medical Devices · near

32
3D Lighting… · lowest

7

What this shows Novimmune's Innovation Score is 32.3/100 (41st percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Novimmune?

Each dot is one of Novimmune’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Novimmune’s own 11.4 claims/patent is at or below the 12.5 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Novimmune vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Novimmune's grants concentrate

Novimmune SA is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2017 (10 grants) versus a trough of 3 in 2021. By volume, Novimmune sits between Nidec Copal Electronics Corporation and Parata Systems, LLC.

Novimmune's three-year grant acceleration

Novimmune SA shows 6 grants in 2022–2024 against only 14 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Nidec Copal

38
Nippon Chemiphar

38
National Chain

38
National Steel Car

38
Ormat

38
Otos Wing

38
Osteomed

38
Parata Systems

38
Novimmune ◀

38

What this shows Novimmune holds 38 patents at rank #8,453, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Novimmune

By rank, the assignees closest to #8,453 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Novimmune's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Novimmune, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), Novimmune ranks #252 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (32 here).

Portola Pharmaceuticals, Inc. 32 Domo, Inc. 32 SPD Swiss Precision Diagnostics GMBH 32 Stat Medical Devices, Inc. 32

Novimmune's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

32 41st percentile higher than 41% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Novimmune SA patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	4	10.5%
2017	10	26.3%
2018	4	10.5%
2019	4	10.5%
2020	7	18.4%
2021	3	7.9%
2022	3	7.9%
2023	3	7.9%

Which technologies does Novimmune SA patent most?

C07K - Peptides 38

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 28

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 23

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 4

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 1

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Novimmune SA's patent record in context - here's where to go next.

Novimmune SA's lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #8,453 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Novimmune SA against Nidec Copal Electronics Corporation, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 32.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.